Comparative genomic hybridization (CGH) was used to detect located at 7q21, is a source of resistance to chemotherapy in changes in DNA copy number in 25 cases of refractory acute AML.
Introduction
Resistance to antileukemic drugs is a major cause of treatment Materials and methods failure in patients with acute myeloid leukemia (AML). [1] [2] [3] [4] [5] About 20-40% of AML patients never achieve remission even Patients with intensive chemotherapy. 4 About half of this group dies in a state of hypoplasia, mainly from infections, and the other Twenty-five patients diagnosed with de novo AML with poor half does not respond to chemotherapy. Furthermore, about prognosis, based either on complete refractoriness against 50-70% of the patients who achieve remission will relapse induction therapy or on a short duration of first remission, due to regrowth of leukemic cells that have survived chemowere included in the study. All patients, except five (Nos 1, therapy, and the prognosis is then poor. A short duration of 10, 14, 20 and 25), died from refractory leukemia; four of the the first remission is a very poor prognostic sign. Based on five survivors received a bone marrow transplant from an results from 150 patients, Hiddemann et al 6 defined refractori-HLA-identical sibling donor. Table 1 shows the clinical and ness against standard first-line chemotherapy as a nonrelaboratory data of the patients. sponse to induction therapy or an early relapse within 6-12 months of first remission. Also, the immunophenotypic features may have diagnostic and prognostic value in AML. The Standard cytogenetics most consistent finding has been a correlation between CD34 expression and a poor response to therapy. However, there BM aspirates were studied at the time of diagnosis by standard are cases with CD34 expression despite their favorable out-G-banding methods. Karyotype abnormalities were described come.
7-9 Drug resistance at the gene level has been thought according to the specifications of the International Standing to be one of the most important determinants of clinical outCommittee on Human Cytogenetic Nomenclature (ISCN, come. 10 Chromosomal aberrations such as monosomy 5 or 7 1995).
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(or deletions of their long arms), or t(9;22), have been associated with a poor response to therapy and considered to indicate a poor prognosis.
11-13
Comparative genomic hybridization Several mechanisms of drug resistance have been demonstrated in preclinical drug trials. Much less is known about CGH was performed, on the same material obtained for the reasons for the poor responsiveness of patients receiving karyotype analysis at diagnosis, using direct fluorochrometreatment for AML. Nevertheless, there is growing evidence conjugated DNAs by methods described previously. 19 for 5 min and hybridized to a slide preparation with normal Briefly, intra-experiment standard deviations for every position in the CGH ratio profiles were calculated further from the varimetaphase spreads denatured in 70% formamide/2 × SSC at 68°C for 2 min. Hybridization was performed at 37°C for ation of the ratio values of all homologous chromosomes within the experiment. Confidence intervals for the ratio pro-48 h. The slides were washed three times in 50% formamide/2 × SSC (pH 7), twice in 2 × SSC, and once in files were then computed by combining them with an empirical inter-experiment standard deviation and by estimating 0.1 × SSC at 45°C, followed by 2 × SSC, 0.1 m NaH 2 PO 4 -0.1 m Na 2 HPO 4 -0.1% NP40 (pH 8), and distilled water at room error probabilities based on the t-distribution. temperature for 10 min each. After air-drying, the slides were counterstained with 4′,6-diamidino-2-phenylindoledihydrochloride (DAPI) (Sigma, St Louis, MO, USA), and then Controls mounted with an antifading medium (Vectashield, Vector Laboratories, Burlingame, CA, USA).
In each CGH experiment, a negative control (peripheral blood DNA from a healthy donor) and a positive control were included. The positive control was a tumor with known changes in DNA copy number (gains at 5q21qter, 9q23qter
Digital image analysis and 12q; high-level amplifications at 8q22qter and 11q14q23; losses at 2q11q22, 3p14q21, 13q11q22 and 22). The hybridizations were analyzed using an Olympus fluorescence microscope and the ISIS digital image analysis system (Metasystems, Altlussheim, Germany) based on an integrated high-sensitivity monochrome charge-coupled device (CCD) Results camera and automated CGH analysis software. Three-color images (red for reference DNA, green for tumor DNA, and Standard cytogenetic analysis blue for counterstaining) were acquired from 8-10 metaphases per sample. Only metaphases of good quality with Chromosomal aberrations were detected in 15 patients (60%). Among the patients with abnormal karyotypes, four patients strong uniform hybridization were included in the analysis. Chromosomes not suitable for CGH analysis were excluded had balanced chromosomal translocations only (Table 2) . (ie chromosomes heavily bent, overlapping, or with overlying artefacts). Chromosomal regions were interpreted as overrepresented when the corresponding ratio exceeded 1.17 Comparative genomic hybridization (gains) or 1.5 (high-level amplification), and as under-represented (losses) when the ratio was less than 0.85. All the CGH revealed changes in DNA copy number in nine patients (36%). DNA copy losses were more frequent than gains and results were confirmed using a 99% confidence interval. constituted 82% of the changes detected (Table 2, Figure 1) . DNA copy losses were detected at 3q11q21 in two cases (Nos 3 and 12) but in one of them no deletion of chromosome 3 Among the patients with abnormal CGH results, the most frequent changes in DNA copy number were losses at 5q was seen by karyotype analysis. In one case (No. 4) CGH did not reveal the del(3)(q21q26) detected by karyotype analysis. detected in four patients (44%), at 7q in seven patients (78%), and at 12p in three patients (33%), with minimal common overlapping regions at 5q14q32, 7q31.2q32 and 12p12, respectively. In one patient, the deletion at 12p12 detected by Controls CGH was not revealed in the karyotype analysis. Losses were also detected at 3p21pter, 3q11q21, 4p, 4q23qter, All negative controls were normal at cut-off values of 0.85 for deletions and 1.17 for gains. The positive controls showed the 6q11q22.2, 8p, 13q21q31, 16, 17, and 18q. Gains at 8q were detected in three patients (33%). Gains at 1p, 2p13p23, 5p, same aberrations that had been detected originally. and 7q21.1q21.3 were also seen. No high-level amplifications were found in any of the cases and gains were always accompanied by losses.
Summary of the results
Changes in DNA copy number were not observed in AML with only balanced translocations or a normal karyotype (14 Overall, the most common sites of aberration were 3q (20%), 5q (20%), 7q (32%), 12p (20%) and 8q (16%). patients). Additionally, CGH did not reveal changes in DNA copy number in two cases (Nos 5 and 24) with chromosomal imbalances present only in 33% of the metaphases analyzed karyotypically. CGH provided valuable information for cases Discussion (Nos 1, 3, 4, 12, 16, 22 ) who had monosomies with marker chromosomes by showing the sum of DNA changes in them.
Our results show that aberrations in chromosomes 5 and 7 are associated with chemotherapy drug resistance as indicated Cases with marker chromosomes and monosomies of chromosomes 5, 7 or 12 by karyotype analysis had only partial by previous cytogenetic studies. However, important findings related to drug resistance in this study were: (1) normal chrodeletions of these chromosomes according to CGH, suggesting rearrangement of the rest of the material in the markers. mosomes in several patients; (2) the absence of high-level
Figure 1
Summary of DNA copy number gains and losses detected by CGH and karyotype analysis. Each bar presents one patient. The empty bar represents the karyotype analysis and the solid bar the CGH analysis on the same sample. Gains are on the right side, losses on the left side. All cases had markers in their karyotype except those marked with 'x'. , translocation breakpoints detected by karyotype; arrows, inversion breakpoints detected by karyotype.
amplifications; and (3) deletions or translocations at 12p.
(Nos 1 and 17). The region includes recently described genes GDID4, CDKN1B and ETV6, [33] [34] [35] [36] which may have relevance CGH provided important information about net gains and losses in patients with complex karyotypes (Nos 1, 3, 4, 12, to the drug resistance in our patients. Breakpoints at 3q21 or 3q26 detected in five patients (Nos 16, 22). Instead of complete monosomy, CGH showed that the deletions are small and interstitial in most cases, suggest-1, 2, 3, 4 and 12) by CGH and/or karyotype analyses coincide with previous cytogenetic studies reporting poor response to ing that the marker chromosomes in these AML cases contained DNA material from the deleted chromosomes. therapy in AML with abnormalities of chromosome 3 at 3q21 and q25-26. 37, 38 In our cases, the common overlapping region of losses in chromosome 5 was 5q14q32, which coincides with pre-
In conclusion, our results by CGH together with standard cytogenetics suggest that DNA copy number losses, but not viously reported cytogenetic data on chromosome 5q deletions. 28 Recently, a myeloid tumor suppressor locus was high-level amplifications, may contribute to the refractoriness of AML. In addition to regions known to be critical for progmapped to 5q31.1, 29, 30 which is consistently lost in cases with 5q aberrations. 31 nosis, aberrations at 12p could be related to a poor prognosis. Since some refractory cases yield normal results, it may be CGH showed that the deletions in chromosome 7, in our cases, had a minimal common overlapping region at that submicroscopic molecular changes are also responsible for resistance to therapy. Further studies using molecular tech7q31.2q32. In addition, gain at 7q21.1q21.3 with simultaneous loss at 7q was detected in case No. 22. Amplifications niques are needed to identify the loci and genes responsible for drug resistance in AML. of the PGY1 gene located at 7q21.1 and deletions at 7q32 imply poor response to chemotherapy 10, 14, 15, 32 and may explain the refractoriness of the disease in these AML cases.
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